PRNewsWire
18 Jul 2026, 18:55 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
REGENXBIO expects to announce topline data from the ATMOSPHERE and ASCENT pivotal trials for wet AMD in Q4 2026. — Pivotal trial results are the primary catalyst for regulatory approval and commercialization, representing the most significant near-term price driver.
+0.60Five-year data for sura-vec in wet AMD showed stable to improved visual acuity and reduced anti-VEGF treatment burden with no new safety signals. — Long-term durability and safety are critical for gene therapy viability, reducing the perceived risk of the upcoming pivotal trials.
+0.40Phase II ALTITUDE trial follow-up for diabetic retinopathy showed 55% of participants achieved a >2 step improvement on the DRSS through 2.5 years. — Positive long-term efficacy in a second major indication expands the total addressable market and diversification for the company.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company announced positive long-term safety and efficacy data for its investigational gene therapy sura-vec.
The company is collaborating on the positive sura-vec trials and expects topline data in Q4 2026.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
3h ago
